英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
001558查看　001558　在百度字典中的解释百度英翻中〔查看〕
001558查看　001558　在Google字典中的解释Google英翻中〔查看〕
001558查看　001558　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • Update 2025: Management of Non‑Small-Cell Lung Cancer - PMC
    Abstract Lung cancer remains the leading cause of cancer-related mortality worldwide Since 2024, the non–small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
  • Non-Small Cell Lung Cancer - Guidelines Detail - NCCN
    Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7 2025
  • FDA Approves Alectinib for ALK-Positive Lung Cancer
    Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . .
    Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study Here, we report long-term outcomes from CROWN after 5 years of follow-up
  • ALK and Lung Cancer - American Lung Association
    ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
  • A comprehensive evaluation of ALK inhibitors in the first . . .
    There are currently six ALK inhibitors available for the first-line treatment of patients diagnosed with ALK-positive advanced non-small cell lung cancer (NSCLC) However, clinicians face challenges in selecting the most appropriate drug for treatment We have collated pertinent evaluative evidence and undertaken a multifaceted assessment of the enrolled medications across five critical
  • Advanced ALK-Positive NSCLC: Treatment Sequencing Insights . . .
    In the field of lung cancer, multiple studies focused on treatment strategies for patients with advanced ALK-positive NSCLC, with the potential to further advance evolving treatment paradigms in
  • ALK-Positive Lung Cancer: Symptoms, Treatment, and Prognosis
    ALK-positive lung cancer is a type of non-small cell lung cancer (NSCLC) in which the cancer cells have a mutation in the anaplastic lymphoma kinase (ALK) gene The mutation is a gene rearrangement: an abnormal fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4) 1





中文字典-英文字典  2005-2009